Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade

BACKGROUND: Subgroup analyses of randomized trials suggest the superiority of immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gastric or gastroesophageal junction adenocarcinoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Randon, Giovanni, Aoki, Yu, Cohen, Romain, Provenzano, Leonardo, Nasca, Vincenzo, Klempner, Samuel J, Maron, Steven B, Cerantola, Riccardo, Chao, Joseph, Fornaro, Lorenzo, Ferrari Bravo, Walter, Ghelardi, Filippo, Ambrosini, Margherita, Manca, Paolo, Salati, Massimiliano, Kawazoe, Akihito, Zhu, Valerie, Cowzer, Darren, Genovesi, Virginia, Lonardi, Sara, Shitara, Kohei, André, Thierry, Pietrantonio, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255232/
https://www.ncbi.nlm.nih.gov/pubmed/37277193
http://dx.doi.org/10.1136/jitc-2023-007104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255232/
https://www.ncbi.nlm.nih.gov/pubmed/37277193
http://dx.doi.org/10.1136/jitc-2023-007104

Ejemplares similares